Oncolytics Biotech Inc. held its Annual General Meeting (AGM) of Shareholders on June 16, 2022. At the meeting, James T. Parsons was elected to the Board of Directors. Leonard Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM.

James T. Parsons BiographyMr. Parsons is a life sciences industry veteran with over two decades of executive experience. He served as the Chief Financial Officer (CFO) of Trillium Therapeutics Inc. from August 2011 through its acquisition by Pfizer in November 2021 for an aggregate purchase price of approximately $2.2 billion. Prior to his time at Trillium, Mr. Parsons provided financial consulting services as the President of Empar Management.

He also previously served as Vice President, Finance, at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences, and CFO and Vice President, Finance and Administration, at Aptose Biosciences Inc. Mr. Parsons has been a Director and the Chair of the Audit Committees of Sernova Corp. and DiaMedica Therapeutics Inc. since 2012 and 2015, respectively.